The Influence of Disease Risk on the Optimal Time Interval between Screens for the Early Detection of Cancer

Abstract

The intervals between screens for the early detection of diseases such as breast and colon cancer suggested by screening guidelines are typically based on the average population risk of disease. With the emergence of ever more biomarkers for cancer risk prediction and the development of personalized medicine, there is a need for risk-specific screening intervals. The interval between successive screens should be shorter with increasing cancer risk. A risk-dependent optimal interval is ideally derived from a cost-effectiveness analysis using a validated simulation model. However, this is time-consuming and costly. We propose a simplified mathematical approach for the exploratory analysis of the implications of risk level on optimal screening interval. We develop a mathematical model of the optimal screening interval for breast cancer screening. We verified the results by programming the simplified model in the MISCAN-Breast microsimulation model and comparing the results. We validated the results by comparing them with the results of a full, published MISCAN-Breast cost-effectiveness model for a number of different risk levels. The results of both the verification and validation were satisfactory. We conclude that the mathematical approach can indicate the impact of disease risk on the optimal screening interval.

Keywords

breast cancer mammography oncology cost-effectiveness analysis simulation methods

Get full access to this article

View all access options for this article.

References

Alexander

Anderson

Brown

. The Edinburgh randomised trial of breast cancer screening: results after 10 years of follow-up. Br J Cancer. 1994;70(3):542–8.

Andersson

Aspegren

Janzon

. Mammographic screening and mortality from breast cancer: the Malmo mammographic screening trial. Br Med J. 1988;297(6654):943–8.

Nyström

Wall

Rutqvist

. Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet. 1993;341(8851):973–8.

Shapiro

Strax

Venet

. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA. 1971;215(11):1777–85.

Baker

. Use of a mathematical model to evaluate breast cancer screening policy. Health Care Manag Sci. 1998;1(2):103–13.

Brandt

Bermejo

Sundquist

Hemminki

. Age of onset in familial breast cancer as background data for medical surveillance. Br J Cancer. 2009;102(1):42–7.

Brandt

A LBJ

Sundquist

Hemminki

. Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start? Breast Cancer Res Treat. 2010;121(1):133–41.

Knudsen

McMahon

Gazelle

. Use of modeling to evaluate the cost-effectiveness of cancer screening programs. J Clin Oncol. 2007;25(2):203–8.

Ramsey

Wilschut

Boer

van Ballegooijen

. A decision-analytic evaluation of the cost-effectiveness of family history-based colorectal cancer screening programs. Am J Gastroenterol. 2010;105(8):1861–9.

10.

Habbema

JDF

Lubbe

JTN

van Oortmarssen

van der Maas

. A simulation approach to cost-effectiveness and cost-benefit calculations of screening for the early detection of disease. Eur J Oper Res. 1987;29(2):159–66.

11.

Habbema

JDF

van Oortmarssen

Lubbe

JTN

van der Maas

. The MISCAN simulation program for the evaluation of screening for disease. Comput Methods Programs Biomed. 1985;20(1):79–93.

12.

van Oortmarssen

Habbema

JDF

van der Maas

. A model for breast cancer screening. Cancer. 1990;66(7):1601–12.

13.

Alagoz

Ayer

Erenay

. Operations Research Models for Cancer Screening. Wiley Encyclopedia of Operations Research and Management Science. New York: John Wiley & Sons; 2010.

14.

Ivy

. Can we do better? Optimization models for breast cancer screening . In: Pardalos

Romeijn

, eds. Handbook of Optimization in Medicine. New York: Springer; 2009. p 1–28.

15.

Zelen

Feinleib

. On the theory of screening for chronic diseases. Biometrika. 1969;56(3):601–14.

16.

Prorok

. The theory of periodic screening II: doubly bounded recurrence times and mean lead time and detection probability estimation. Adv Appl Probab. 1976;8(3):460–76.

17.

Day

Walter

. Simplified models of screening for chronic disease: estimation procedures from mass screening programmes. Biometrics. 1984;40(1):1–13.

18.

Shwartz

. A mathematical model used to analyze breast cancer screening strategies. Oper Res. 1978;26(6):937–55.

19.

Weiss

Lincoln

. Analysis of repeated examinations for the detection of occult disease. Health Serv Res. 1966;1(3):272–86.

20.

Kirch

RLA

Klein

. Examination schedules for breast cancer. Cancer. 1974;33(5):1444–50.

21.

Zelen

. Optimal scheduling of examinations for the early detection of disease. Biometrika. 1993;80(2):279–93.

22.

Lee

Zelen

. Scheduling periodic examinations for the early detection of disease: applications to breast cancer. J Am Stat Assoc. 1998;93(444):1271–81.

23.

Parmigiani

. On optimal screening ages. J Am Stat Assoc. 1993;88(422):622–8.

24.

Parmigiani

. Timing medical examinations via intensity functions. Biometrika. 1997;84(4):803–16.

25.

Parmigiani

Kamlet

. A cost-utility analysis of alternative strategies in screening for breast cancer. In: Gatsonis

Hodges

Kass

Singpurwalla

, eds. Bayesian Statistics in Science and Technology: Case Studies. New York: Springer; 1993. p 390–402.

26.

Eddy

. Screening for Cancer: Theory, Analysis, and Design. Englewood Cliffs (NJ): Prentice-Hall; 1980.

27.

Eddy

. ACS report on the cancer-related health checkup. CA Cancer J Clin. 1980;30(4):193–240.

28.

Maillart

Ivy

Ransom

Diehl

. Assessing dynamic breast cancer screening policies. Oper Res. 2008;56(6):1411–27.

29.

Ayer

Alagoz

Stout

. OR forum—a POMDP approach to personalize mammography screening decisions. Oper Res. 2012;60(5):1019–34.

30.

de Gelder

Bulliard

J-L

de Wolf

. Cost-effectiveness of opportunistic versus organised mammography screening in Switzerland. Eur J Cancer. 2009;45(1):127–38.

31.

Walter

Day

. Estimation of the duration of a pre-clinical disease state using screening data. Am J Epidemiol. 1983;118(6):865–86.

32.

Gao

Chia

K-S

F-C

E-H

Machin

. Interval cancers following breast cancer screening in Singaporean women. Int J Cancer. 2002;101(5):475–9.

33.

Jansen

JTM

Zoetelief

. MBS: a model for risk benefit analysis of breast cancer screening. Br J Radiol. 1995;68(806):141–9.

34.

Jansen

JTM

Zoetelief

. Optimisation of mammographic breast cancer screening using a computer simulation model. Eur J Radiol. 1997;24(2):137–44.

35.

Weinstein

Stason

. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med. 1977;296(13):716–21.

36.

Shen

Zelen

. Screening sensitivity and sojourn time from breast cancer early detection clinical trials: mammograms and physical examinations. J Clin Oncol. 2001;19(15):3490–9.

37.

Bulliard

De Landtsheer

Levi

. Results from the Swiss mammography screening pilot programme. Eur J Cancer. 2003;39(12):1761–9.

38.

Boersma

Broere

Postma

. Quantification of the potential impact of cost-effectiveness thresholds on Dutch drug expenditures using retrospective analysis. Value Health. 2010;13(6):853–6.

39.

Tyrer

Duffy

Cuzick

. IBIS Breast Cancer Risk Evaluation Tool. 7th ed. London: Wolfson Institute of Preventive Medicine; 2013. Available at www.ems-trials.org/riskevaluator/. Accessed August 1, 2013.

40.

Tyrer

Duffy

Cuzick

. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23(7):1111–30.

41.

Brown

. Economic considerations in breast cancer screening of older women. J Gerontol. 1992;47(S):51–8.

42.

D’Souza

Tseng

Pauly

. A strategy for blood biomarker amplification and localization using ultrasound. Proc Natl Acad Sci U S A. 2009;106(40):17152–7.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.05 MB

0.02 MB

0.06 MB